Group 1: CRO Industry Insights - Since 2025, domestic CRO orders have shown a trend of simultaneous volume and price increase, benefiting from the overseas expansion of innovative drugs and stable financing recovery [1] - Multiple CROs have accelerated new order signing quarterly, achieving double-digit growth in project volume, with a price increase trend observed in experimental monkeys, safety evaluation quotes, and clinical project pricing since Q4 [1] - The performance of CROs is expected to enter an improvement cycle by 2026, driven by strong customer demand and the continuous strengthening of China's global competitiveness in innovative drugs [1] Group 2: Innovative Drug Market Dynamics - Despite previous adjustments in the innovative drug sector, the logic of strengthening global competitiveness, successful overseas expansion, and realization of commercial profits remains unchanged [1] - In the past two years, China has experienced a "big year" for innovative drug overseas expansion, with record highs in both the number and value of licensing-out transactions [1] - In 2025, the number of new drug license-out transactions in China is expected to reach 158, with a total transaction scale of $135.7 billion and an upfront payment scale of $7 billion, marking a ten-year high in both transaction quantity and value [1] Group 3: Brain-Computer Interface (BCI) Developments - The BCI sector is advancing with multiple technological routes underpinned by AI integration and supportive policies, accelerating the commercialization growth cycle [2] - BCIs serve as a direct information exchange channel between the biological brain and external devices, enabling brain function replacement, repair, enhancement, and optimization [2] - In the global landscape, the US leads in invasive technologies while China has made breakthroughs in non-invasive and language decoding fields, with both countries showing minimal technological lag [2] Group 4: Policy and Capital Support for BCI - The BCI industry is included in the "14th Five-Year Plan," with various policies supporting technological innovation, application scenarios, and medical insurance payments, facilitating industry standardization and clinical transformation [2] - Capital investment in the BCI sector has significantly increased, with a multiple growth in financing events and amounts expected by 2025, indicating a strong recovery in investor interest [2] - Although the financing structure shows early-stage characteristics, leading companies have received substantial capital injections, leading to a gradual emergence of industrial clustering effects [2]

Group 1 - The core viewpoint emphasizes that the combination of technology and cyclical sectors remains a key investment theme, with expectations of PPI turning positive driving EPS growth and liquidity support [1] - The article highlights the importance of focusing on stable growth in end-user sectors and the commercialization of ToB applications, particularly in areas such as computing hardware, energy storage, AI applications, and intelligent driving [1] - The Guotai Science and Innovation ETF (588360) tracks the Science and Innovation 50 Index (931643), which includes 50 large-cap emerging industry companies from the Sci-Tech and ChiNext boards, reflecting the overall performance of representative emerging industries [1] Group 2 - The index focuses on industries such as electronics, power equipment, communications, and biomedicine, emphasizing technological attributes and innovative growth, with a relatively balanced industry allocation [1] - The cyclical sectors are expected to show significant price and valuation elasticity during the phase of PPI turning positive, with reduced competition potentially leading to improved performance in sectors like non-ferrous metals, chemicals, machinery, steel, and building materials [1]

Group 1 - The JPM 2026 conference revealed innovative opportunities in the pharmaceutical and medical device sectors, particularly in the IO plus field where the trend of using VEGF dual antibodies in multiple indications is becoming established [1] - There is a focus on multinational corporations (MNCs) and leading biotech companies developing dual antibodies and combinations with monoclonal antibodies targeting other immune-related sites [1] - In the ADC (Antibody-Drug Conjugate) area, attention is drawn to first-in-class (FIC) products for large indications, new indications for major products, and advancements in dual toxin/new toxin ADC technologies, which are leading directions for domestic innovative drugs [1] Group 2 - The ETF Guotai (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20%, and selects listed companies engaged in biopharmaceuticals, chemical pharmaceuticals, traditional Chinese medicine, and medical services [2] - The index emphasizes the R&D investment and technological leadership of constituent companies, focusing on high-growth potential in the pharmaceutical health sector [2] - The ETF aims to reflect the overall performance of listed companies related to innovative biopharmaceuticals [2]

临近春节档电影上映，电影板块异动频频。实际上，影视传媒板块自年初以来始终是热门投资方向。数据显示，截至2月10日，国泰影视主题ETF和银华 影视主题ETF年内涨幅均超30%，暂居ETF涨幅榜第二、第三位；广发传媒ETF、鹏华传媒ETF年内涨幅均超过25%，分列第四、第五位。另有1只文娱传 媒ETF年内涨幅超20%，暂居第九位。 双重催化 "除春节档临近外，影视股异动还有多重核心驱动因素。"排排网财富公募产品运营曾方芳向《国际金融报》记者表示：一是行业经历供给侧出清后迎来复 苏拐点，政策优化与优质内容供给增加，叠加文娱消费需求释放；二是板块估值处于历史相对低位，与改善的基本面形成背离，估值修复需求吸引资金； 三是影视IP通过游戏、衍生品等多元变现模式逐步成熟，提升长期盈利预期；四是内容出海加速，融资客持续抢筹龙头标的，资金面提供支撑。 2月10日，A股市场全天震荡，个股表现分化，沪指窄幅收涨。板块方面，文化传媒板块领涨，1只影视ETF（交易型开放式指数基金）尾盘涨停，多只影 视、游戏、传媒主题ETF涨幅位居全市场前列。截至2月10日，今年以来影视传媒相关主题ETF表现在所有ETF中领跑。 | 序号 代码 | | ...

- The report introduces the **RSI (Relative Strength Index)** as a quantitative factor. The construction idea is to measure the relative strength of price movements over a specific period to identify overbought or oversold conditions. The formula is: $ RSI = 100 - \frac{100}{1 + RS} $, where $ RS $ is the ratio of the average gain to the average loss over a 12-day period. $ RSI > 70 $ indicates an overbought market, while $ RSI < 30 $ indicates an oversold market[2] - Another quantitative factor mentioned is **Net Subscription (NETBUY)**, which measures the net inflow or outflow of funds in ETFs. The formula is: $ NETBUY(T) = NAV(T) - NAV(T-1) \times (1 + R(T)) $, where $ NAV(T) $ is the net asset value on day $ T $, $ NAV(T-1) $ is the net asset value on the previous day, and $ R(T) $ is the return on day $ T $[2] - The report also highlights **Intraday Trend Analysis**, which uses 5-minute interval transaction prices to construct intraday price trends. Red dots mark the highest and lowest prices of the day. However, due to data limitations, some intraday data may be incomplete[2] - The **Institutional Holding Ratio** is another factor, calculated based on the latest annual or semi-annual reports of ETFs, excluding holdings by linked funds. The data is an estimate and may have deviations[3] - The report provides detailed tracking of various ETFs categorized into "broad-based" and "thematic" indices, such as CSI 300, CSI 500, and sector-specific indices like non-bank financials and dividends. These indices serve as benchmarks for ETF performance evaluation[2][4] - The report includes a comprehensive table of ETF performance metrics, such as RSI values, net subscription amounts, and institutional holding ratios, for various ETFs tracking indices like CSI 300, CSI 500, CSI 1000, and others. For example, the RSI for CSI 300 ETFs ranges from 50.04 to 54.02, while net subscription values vary significantly across ETFs[4] - The report also tracks thematic ETFs, such as those focused on semiconductors, artificial intelligence, and renewable energy, providing performance metrics like RSI, net subscription, and institutional holding ratios. For instance, the RSI for semiconductor ETFs ranges from 49.16 to 50.40, while net subscription values show significant variation[7]

AI产业加速落地，科创算力迎布局良机，资金面看，科创人工智能ETF国泰（589110）近期获大额净申 购，资金逆势流入迹象显著，今日盘中涨近2%。 券商指出，2026年为AI商业化落地关键年，大模型迭代、智能体应用爆发、国产算力自主可控进程提 速，叠加政策支持与产业景气上行，科创板AI企业具备高研发壁垒与成长弹性，板块估值与业绩双击 可期。 科创人工智能ETF国泰（589110）跟踪科创AI指数（950180），从科创板精选30家布局AI基础资源、技 术研发与应用落地的优质企业，覆盖算力硬件、核心软件、行业解决方案等关键环节，精准把握科创板 AI赛道成长红利，弹性突出。 （文章来源：每日经济新闻） ...

（文章来源：每日经济新闻） 华创证券指出，科技+顺周期仍是年度配置主线。PPI转正预期带动EPS接棒流动性，问增长要收益，科 创配置价值仍在。康波周期下的科技博弈有望继续打开估值上限，应重视端侧稳健增长、应用侧ToB商 业化落地，具体可关注算力硬件、储能、AI应用、智能驾驶等领域。 科创200ETF国泰（589220）跟踪的是科创200指数（000699），单日涨跌幅限制达20%，该指数从科创 板市场中选取市值较大、流动性较好的200只股票作为指数样本，以反映科创板市场的整体表现。指数 样本覆盖了多个高新技术产业和战略性新兴产业领域，包括信息技术、生物医药、新能源等，体现了较 强的创新性和成长性特征。 ...

Core Viewpoint - The article emphasizes the strategic direction of state-owned enterprises during the "14th Five-Year Plan" period, focusing on the integration and optimization of resources, innovation, and the development of emerging industries [1] Group 1: Strategic Initiatives - State-owned capital will drive the "three concentrations" strategy to promote restructuring and optimization [1] - There will be a strong emphasis on independent and original innovation, alongside the implementation of the "AI+" special action plan [1] - The focus will be on emerging industries such as renewable energy, aerospace, low-altitude economy, quantum technology, and 6G, with future planning for intelligent embodiment, biomanufacturing, marine energy, and green shipping [1] Group 2: Industry and Market Performance - The CSI A500 index emphasizes industry balance and leading companies, providing a more diversified and growth-oriented investment opportunity compared to the CSI 300 index [1] - As of the end of 2025, the CSI A500 index has increased by 464.28% since its base date, outperforming the CSI 300 index, which has risen by 361.15%, resulting in an excess return of 103.13% [1] - The number of clients for the Guotai CSI A500 ETF is the highest in its category, being more than three times that of the second-ranked competitor [1]

2月9日，港股通红利ETF广发（520900）交投活跃，截止午盘涨0.56%，成交额7273.71万元。国泰海通 表示，海外金融紧缩预期边际改善，国内政策重心正转向内需主导。恐慌性抛售后，中国股市已至关键 位置，建议持股过节。新兴科技是主线，价值也会有春天。银河证券表示，"轻仓持股过节"是一种审慎 且符合历史规律的合理策略，既规避了节前市场缩量调整的波动风险，又保留了节后春季行情的参与机 会。供需格局改善与行业盈利修复带动的"反内卷"概念，以及估值具备安全边际的红利资产，配置逻辑 依然清晰。港股通红利ETF广发（520900）及其场外联接（022719/022720）为投资者提供了一键布局 港股红利资产的便捷入口，让稳健收益与长期价值兼得。 来源：视频滚动新闻 ...

Group 1 - The public FOF market has seen a surge in activity at the beginning of 2026, with new products raising nearly 30 billion yuan, driven by strong demand from bank clients for diversified asset allocation in a low-interest-rate environment [1] - FOF is transitioning from a "fixed income+" dominated phase to a "multi-asset allocation" phase, utilizing a combination of stocks, bonds, commodities, and overseas assets to help investors manage market volatility and achieve stable growth [1] - On February 6, the A-share market experienced significant fluctuations, with the Shanghai Composite Index closing down 0.25% at 4065.58 points, and total market turnover reaching 2.16 trillion yuan, a decrease of 30.8 billion yuan from the previous trading day [1] Group 2 - On February 6, only one new fund was launched, primarily an equity fund, with the E Fund Hang Seng A-Share Electric Grid Equipment ETF aiming to raise 8 billion yuan; 16 funds distributed dividends, with the highest being 0.8050 yuan per 10 shares for the Penghua Harvest Bond Fund [2] - A total of 43 funds are set to be launched from February 9 to the end of the month, with a focus on equity funds, which account for nearly 80% of the new offerings, as institutions prepare for a potential spring market rally [2] - Fund managers are shifting strategies in response to increased market volatility, focusing on specific sectors or enhancing bottom-up stock selection, with an emphasis on preserving returns over seeking high gains in 2026 [2] Group 3 - Public fund institutions are increasingly launching Hong Kong-themed funds, with over 30 such funds reported since the beginning of the year, reflecting optimism about long-term investment opportunities in Hong Kong stocks, particularly in technology, consumer, and dividend sectors [3]